The proportion of Th17 cells in patients with systemic sclerosis: a Meta-analysis
10.3760/cma.j.cn141217-20210816-00322
- VernacularTitle:辅助性T细胞17在系统性硬化病患者中的临床意义荟萃分析
- Author:
Yanrong LI
1
;
Wei SONG
;
Yun LI
;
Mengying FAN
;
Xingru WANG
;
Jiaying LI
;
Shengxiao ZHANG
;
Caihong WANG
Author Information
1. 山西医科大学第二临床医学院，太原 030001
- Keywords:
Scleroderma, systemic;
Th17 cells;
Meta-analysis
- From:
Chinese Journal of Rheumatology
2023;27(4):236-242
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To clarify peripheral Th17 level in SSc patients and its correlation with disease.Methods:Chinese databases CNKI, CBM, Wanfang and VIP, and English databases PubMed, EMBASE, Web of Science, Cochrane Library and Science Direct were searched to collect a case-control study on the content of Th17 cells in peripheral blood of patients with SSc. The papers published when the database was first developed in 25 February 2021. Meta-analysis was conducted using Stata 12.0 software, and I2 and Egger tests were used to evaluate the heterogeneity and publication bias between studies. Results:A total of 26 case-controls were included in the study, including 1 160 patients with SSc and 778 healthy controls. Overall, the percentage of Th17 cells in SSc patients was higher than in healthy controls [SMD(95% CI)=1.85 (1.33, 2.38), P<0.001], which was most significant in IL-17 +Th17 concentration [SMD(95% CI)=1.88 (1.28, 2.48), P<0.001]. As for disease activity, the proportion of Th17 cells in active SSc patients was much higher than those of patients in remission [SMD(95% CI)=1.92 (1.12, 2.71), P<0.001]. SSc patients had a reduced Th17 level after receiving DMARDs treatment [SMD(95% CI)=-0.74 (-1.05, -0.42), P=0.029]. Conclusion:The number of Th17 cells increase significantly in the peripheral blood of patients with SSc, and is related to disease activity. DMARDs can be used to treat this disease by downregulating Th17 levels.
